The work of Daniel Choi of the Perelman School of Medicine is highlighted as he and his team investigated the effect of anti-vascular endothelial growth factor therapies in patients over the long term and overall found no association between the treatments and the risk of chronic kidney disease or end-stage renal disease.
https://bit.ly/3vYdl0V Ophthalmology Times